ASU PhD candidate selected as Emerging Scholar by Network of Schools of Public Policy, Affairs and Administration

October 16, 2019

For the second time in three years, a doctoral candidate from Arizona State University’s School of Public Affairs has been named an Emerging Scholar of the Network of Schools of Public Policy, Affairs and Administration (NASPAA).

PhD student Fengxiu Zhang was chosen in 2019 because she shows “excellent promise in achieving a faculty position upon graduation,” according to the letter announcing the award. Fengxiu Zhang, a female with long dark hair and black-rimmed glasses faces the camera, smiling in a dark top Fengxiu Zhang. Download Full Image

“Fengxiu Zhang is a highly promising early career scholar with an impressive record,” said Professor Eric Welch, director of the school’s Center for Science, Technology and Environmental Policy Studies and Zhang’s academic adviser. “Her research, examining adaptation of public agencies in response to extreme events, will contribute significantly to the field of public management.”

The honor includes a $350 stipend and travel expenses paid for Zhang to attend the NASPAA Annual Conference on Oct. 16-19 in Los Angeles.

“I am deeply honored to receive this award,” Zhang said. “I study public organization adaptation to extreme events, which is an important, but rarely examined, topic in public administration. I see this award as an important recognition of the significance of my work.”

At a panel discussion held after receiving the award at an Oct. 18 luncheon, she will give a 10-minute presentation to educators, many of whom have hiring authority.

“The NASPAA presentation will be a great opportunity to showcase my work and myself as a researcher to leaders from many other schools in public administration,” Zhang said. “I particularly look forward to interactions with prospective employers to learn about opportunities where I can continue my research after completing my doctoral degree.”

Zhang is one of three students from 282 schools honored with the NASPAA Emerging Scholars Award this year. Others are Andrew Osorio, School of Public Affairs and Administration, University of Kansas, and David Schwegman, Maxwell School of Citizenship and Public Affairs, Syracuse University.

In 2017, School of Public Affairs then-doctoral candidate Federica Fusi, who is now an assistant professor at the University of Illinois at Chicago, won the Emerging Scholar Award from NASPAA. School of Public Affairs is an academic unit of the Watts College of Public Service and Community Solutions.

ASU Biodesign startup receives Fast Lane Award from AZBio

October 16, 2019

The Arizona Bioindustry Association (AZBio) has named OncoMyx Therapeutics, Inc., an Arizona State University Biodesign Institute startup, as a Fast Lane Company for 2019.

Other Arizona companies to receive the distinction during Arizona Biosciences Week this year were Biosensing Instrument in Tempe and Gt Medical Technologies in Mesa. Grant McFadden, director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy, is the co-founder of OncoMyx. Download Full Image

The annual award recognizes Arizona bioscience companies that have arrived at significant milestones during the past 18 months. Impact is measured by such factors as clinical results, regulatory approvals, certifications, collaborations, funding awards, product launches, job growth or product sales milestones.

OncoMyx was incorporated in 2018 by founders Grant McFadden, director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy, company CEO Steve Potts and COO Michael Wood. The company aims “to develop oncolytic immunotherapies with an unambiguous, promotable advantage that eradicate hard-to-cure cancers.”

The company is creating tumor-destroying immunotherapies based on the myxoma virus (MYXV), a poxvirus that causes localized skin infections in rabbits, but is safe in humans and any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. McFadden has pioneered the MYXV field and is widely regarded as a top oncolytic virus (OV) expert.

McFadden and his collaborators have spent the past two decades evaluating MYXV in a wide variety of tumor models. The natural target of the virus is the European rabbit, in which it causes a lethal disease. Because it only grows in rabbit cells or cancer cells, it does not infect healthy human tissue. In humans, the virus is harmless, except when it encounters a cancer cell. McFadden’s research team has successfully targeted various types of cancers.

According to McFadden, “OVs are emerging as a new pillar of cancer care to complement the effectiveness of immunotherapies such as immune checkpoint blockade. The best-in-class MYXV platform is the only OV in development that is collectively a nonhuman pathogen, inherently immuno-stimulatory, easily multi-armed, and systemically delivered.”

In June 2019, OncoMyx announced the completion of a $25 million series A financing led by Boehringer Ingelheim Venture Fund (BIVF), Delos Capital and Xeraya Capital with participation from Korea Investment Partners (KIP), City Hill Ventures and Madison Partners. OncoMyx is using the proceeds to advance development of its lead oncolytic virus therapeutic program for the treatment of various cancers.

OncoMyx is currently being launched in Phoenix to test next-generation viruses in human clinical trials against a variety of human cancers.

OncoMyx will spearhead the next-stage development plans of oncolytic myxoma virus to seek FDA approval and conduct the first human clinical trials, using their patented systemic delivery approach. The company will capitalize on McFadden’s two decades of research into the potential of oncolytic viruses. McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.

Preclinical studies in mice and testing on cancer patient samples from Mayo Clinic in Scottsdale have demonstrated encouraging immune responses against tumors. These data points build upon the continued clinical validation of OncoMyx’s platform to expand the boundaries of cancer treatment and potentially benefit a large group of patients.

Kanad Das, executive director of Boehringer Ingelheim Venture Fund said, “We look forward to working with the team to develop drugs that help improve patients’ lives across a range of malignancies.”

For more information about Grant McFadden and his work with the rabbit virus, visit “Treating cancer with a rabbit trick" at Ask a Biologist.

Written by Dianne Price, Biodesign Institute